These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1778855)

  • 1. The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.
    Wise R; Andrews JM; Thornber D
    J Antimicrob Chemother; 1991 Aug; 28(2):239-48. PubMed ID: 1778855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
    Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity and beta-lactamase stability of FK482, a new oral cephalosporin.
    Neu HC; Saha G; Chin NX
    Antimicrob Agents Chemother; 1989 Oct; 33(10):1795-800. PubMed ID: 2589845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.
    Briggs BM; Jones RN; Erwin ME; Barrett MS; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(5):425-34. PubMed ID: 1797457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.
    Cohen MA; Joannides ET; Roland GE; Meservey MA; Huband MD; Shapiro MA; Sesnie JC; Heifetz CL
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):31-9. PubMed ID: 8026155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of cefdinir (CI-983; FK-482) against staphylococci, gram-negative bacilli and respiratory tract pathogens.
    Scriver SR; Willey BM; Low DE; Simor AE
    Eur J Clin Microbiol Infect Dis; 1992 Jul; 11(7):646-52. PubMed ID: 1396778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefdinir against respiratory pathogens isolated in Sicily with reference to beta-lactamase production.
    Blandino G; Aleo G; Caccamo F; Nicolosi VM; Siracusa V; Speciale A
    J Chemother; 1996 Jun; 8(3):193-9. PubMed ID: 8808715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antibacterial activity of FK482, a new orally active cephalosporin.
    Mine Y; Kamimura T; Watanabe Y; Tawara S; Matsumoto Y; Shibayama F; Kikuchi H; Takaya T; Kuwahara S
    J Antibiot (Tokyo); 1988 Dec; 41(12):1873-87. PubMed ID: 3264828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.
    Sultan T; Baltch AL; Smith RP; Ritz W
    Chemotherapy; 1994; 40(2):80-91. PubMed ID: 8131638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil.
    Bauernfeind A; Jungwirth R
    Infection; 1991; 19(5):353-62. PubMed ID: 1800377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro activity of cefpodoxime: a comparison with other oral cephalosporins.
    Wise R; Andrews JM; Ashby JP; Thornber D
    J Antimicrob Chemother; 1990 Apr; 25(4):541-50. PubMed ID: 2351624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity and beta-lactamase stability of LY163892.
    Cao C; Chin NX; Neu HC
    J Antimicrob Chemother; 1988 Aug; 22(2):155-65. PubMed ID: 3263352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
    Gerlach EH; Jones RN; Allen SD; Koontz FP; Murray PR; Pfaller MA; Washington JA; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Aug; 15(6):537-43. PubMed ID: 1424507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of BMY-28100, a new oral cephalosporin.
    Eliopoulos GM; Reiszner E; Wennersten C; Moellering RC
    Antimicrob Agents Chemother; 1987 Apr; 31(4):653-6. PubMed ID: 3496846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies with Bay V 3522, a new oral cephalosporin.
    Thomson KS; Sanders CC; Sanders WE
    Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro antibacterial activity of cefdinir against isolates of respiratory tract pathogens in children].
    Lu Q; Zhang H; Che DT; Li WH
    Zhonghua Er Ke Za Zhi; 2004 Sep; 42(9):697-700. PubMed ID: 15482675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
    Chin NX; Gu JW; Neu HC
    Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo therapeutic efficacy of cefdinir (FK482), a new oral cephalosporin, against Staphylococcus aureus and Haemophilus influenzae in mouse infection models.
    Cohen MA; Wold SA; Meservey MA; Gage JW; Heifetz CL; Mailloux GB; Roland GE; Yoder SL
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):41-7. PubMed ID: 8026156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.